Synopsis: The proposed agreement permits Stevedoring Co. to provide or arrange to have provided to Senator Linie terminal services as specified in this Agreement and Appendices. As consideration, Senator Linie agrees to compensate Stevedoring Co. in accordance with the provisions of the rate schedule(s) set forth in Appendix I of this agreement. The parties have requested a shortened review period.

By Order of the Federal Maritime Commission.

Dated: May 15, 1987.

Joseph C. Polking,

Secretary.

[FR Doc. 87-11440 Filed 5-19-87; 8:45 am]

BILLING CODE 6730-01-M

FEDERAL MEDIATION AND CONCILIATION SERVICE

President's Advisory Committee on Mediation and Conciliation; Meeting

Pursuant to section 10 of the Federal Advisory Committee Act (Pub. L. 92-463, as amended) notice is hereby given that a meeting of the President's Advisory Committee on Mediation and Conciliation will be held on Tuesday, June 9, 1987 from 9:00 a.m. to 5:00 p.m., Wednesday, June 10, 1987 from 9:00 a.m. to 5:00 p.m. and Thursday, June 11, 1987 from 9:00 a.m. to 5:00 p.m., at the Hyatt Regency Hotel, Skyway Meeting Room #268, 151 East Wacker Drive, Chicago, Illinois 60601.

The purpose of the meeting is to obtain the views of representatives of labor and management, and other qualified individuals, with regard to labor-management goals and objectives expected to be achieved within a period of five years. A hearing procedure will be followed in which the views of witnesses will be transcribed for the record.

The meeting will be open to the public. Interested persons may file written statements with the Committee, and subject to reasonable Committee procedures may also make oral statements on matters germane to subjects under consideration at the meeting.

Further information regarding this meeting may be obtained from Mr. Dennis R. Minshall, Executive Director, President's Advisory Committee on Mediation and Conciliation, Federal Mediation and Conciliation Service, 2100 K Street, NW., Washington, DC 20427, or call (202) 653-5290.

Dated: May 14, 1987.

Kay McMurray,

Director, Federal Mediation and Conciliation Service.

[FR Doc. 87-11473 Filed 5-19-87; 8:45 am]

BILLING CODE 6372-01-M

FEDERAL RESERVE SYSTEM

Lizton Financial Corp. et al.; Applications To Engage de Novo in Permissible Nonbanking Activities

The companies listed in this notice have filed an application under § 225.23(a)(1) of the Board's Regulation Y (12 CFR 225.23(a)(1)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to commence or to change *de novo*, either directly or through a subsidiary, in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than June 11, 1987.

A. **Federal Reserve Bank of Chicago** (David S. Epstein, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. *Lizton Financial Corporation,* Lizton, Indiana; to engage de novo through its subsidiary, Schorling & Associates, Inc., Lizton, Indiana, in data processing services and management consulting advice pursuant to §§ 225.25(b)(7) and (b)(11) of the Board's Regulation Y.

B. **Federal Reserve Bank of San Francisco** (Harry W. Green, Vice President) 101 Market Street, San Francisco, California 94105:

1. *Valley Capital Corporation,* Las Vegas, Nevada; to engage *de novo* through its subsidary, Valley Electronic Services, Inc., Las Vegas, Nevada, in data processing and transmission services and the issuance of retail money orders and similar consumer-type payment instruments pursuant to §§ 225.25(b)(7) and (b)(12) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, May 14, 1987.

James McAfee,

Associate Secretary of the Board.

[FR Doc. 87-11445 Filed 5-19-87; 8:45 am]

BILLING CODE 6210-01-M

Susquehanna Bancshares, Inc., et al.; Formation of; Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulation Y (12 CFR 225.14) to become a bank holding company or to acquire a bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Unless otherwise noted, comments regarding each of these applications must be received not later than June 11, 1987.

A. **Federal Reserve Bank of Philadelphia** (Thomas K. Desch, Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105:

1. *Susquehanna Bancshares, Inc.*, Lititz, Pennsylvania; to acquire 100 percent of the voting shares of Spring Grove National Bank, Spring Grove, Pennsylvania.

B. **Federal Reserve Bank of Chicago** (David S. Epstein, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. *D.S.B. Bankshares, Inc.*, Randolph, Wisconsin; to become a bank holding company by acquiring at least 80 percent of the voting shares of Dairymans State Bank, Randolph, Wisconsin.

2. *Firstbank Corp.*, Alma, Michigan; to acquire 100 percent of the voting shares of Comerica Bank—Central, Shepher, Michigan, and Comerica Bank—West Branch, N.A., West Branch, Michigan.

C. **Federal Reserve Bank of Minneapolis** (James M. Lyon, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota, 55480:

1. *Fillmore County Bancshares, Inc.*, Canton, Minnesota; to become a bank holding company by acquiring 97.4 percent of the voting shares of Canton State Bank, Canton, Minnesota.

Board of Governors of the Federal Reserve System, May 14, 1987.

James McAfee,

Associate Secretary of the Board

[FR Doc. 87–11446 Filed 5–19–87; 8:45 am]

BILLING CODE 6210–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 87F–0150]

Ciba-Geigy Corp.; Filing of Food Additive Petition

AGENCY: Food and Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Ciba-Geigy Corp. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of dimethyl succinate polymer with 4-hydroxy-2,2,6,6,-tetramethyl-1-piperidineethanol as a stabilizer for olefin polymers and ethylene-vinyl acetate copolymers complying with 21 CFR 177.1520 and 21 CFR 177.1350, respectively.

FOR FURTHER INFORMATION CONTACT: Julius Smith, Center for Food Safety and Applied Nutrition (HFF–335), Food and Drug Administration, 200 C Street SW., Washington, DC 20204, 202–472–5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(B)(5))), notice is given that a petition (FAP 7B3991) has been filed by Ciba-Geigy Corp., Three Skyline Dr., Hawthorne, NY 10532, proposing that § 178.2010 *Antioxidants and/or stabilizers for polymers* (21 CFR 178.2010) be amended to provide for the safe use of dimethyl succinate polymer with 4-hydroxy-2,2,6,6-tetramethyl-piperidineethanol as a stabilizer for olefin polymers and ethylene-vinyl acetate copolymers complying with 21 CFR 177.1520 and 21 CFR 177.1350, respectively.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: May 11, 1987.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 87–11452 Filed 5–19–87; 8:45 am]

BILLING CODE 4160–01–M

Advisory Committee; Meeting

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

Meeting: The following advisory committee meeting is announced:

Technical Electronic Product Radiation Safety Standards Committee

Date, time, and place. June 22, 10 a.m. and June 23, 8: 30 a.m., Rm. 416–418, Twinbrook Bldg., 12720 Twinbrook Parkway, Rockville, MD.

Type of meeting and contact person. Open public hearing, June 22, 10 a.m. to 11 a.m.; open committee discussion, 11 a.m. to 5 p.m.; open committee discussion, June 23, 8:30 to 12 m.; Arlene R. Underdonk, Center for Devices and Radiological Health (HFZ–83), Food and Drug Administration, 12720 Twinbrook Parkway, Rockville, MD 20857, 301–443–3426.

General function of the committee. The committee provides advice and consultation to the Commissioner of Food and Drugs on the technical feasibility, reasonableness, and practicability of performance standards for electronic products to control the emission of radiation from such products, and may recommend electronic product radiation safety standards to the Commissioner for his consideration.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before June 12, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. The committee will discuss draft amendments to the performance standard for diagnostic x-ray systems and their major components (21 CFR 1020.30, 1020.31, and 1020.32) and receive an update on the progress of other retrospective reviews of performance standards.

FDA public advisory committee meetings may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. whether or not it also includes any of the other three portions will depend upon the specific meeting involved. There are no closed portions for the meetings announced in this notice. The dates and times reserved for the open portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guidelines (Subpart C of 21 CFR Part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR Part 14. Under 21 CFR 10.205, representatives

of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's pubic administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this **Federal Register** notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.

Persons interested in specific agenda items to be discussed in open session may ascertain from the contact person the approximate time of discussion.

Details on the agenda, questions to be addressed by the committee, and a current list of committee members are available from the contact person before and after the meeting. Transcripts of the opem portion of the meeting will be available from the Freedom of Information Office (HFW–35), Food and Drug Administration, Rm. 12A–16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (FHA–305), Food and Drug Administration, Rm. 4–62, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting will be available from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

This notice is issued under section 10(a) (1) and (2) of the Federal Advisory Committee Act (Pub. L. 92–463, 86 Stat. 770–776 (5 U.S.C. App. I)), and FDA's regulations (21 CFR Part 14) on advisory committees.

Dated: May 14, 1987.

John M. Taylor,

Associate Commissioner for Regulatory Affairs.

[FR Doc. 87–11453 Filed 5–19–87; 8:45 am]

BILLING CODE 4160–01–M

Consumer Participation; Open Meetings

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the following consumer exchange meetings:

Atlanta District Office, chaired by John H. Turner, District Director. The topics to be discussed are health messages on food labels and cholesterol labeling.

DATE: Tuesday, May 26, 1987, 11 a.m. to 1 p.m.

ADDRESS: South Fulton Government Annex, 5600 Stonewall Tell Rd., Atlanta, GA 30329.

FOR FURTHER INFORMATION CONTACT: Carolyn Hommel, Consumer Affairs Officer, Food and Drug Administration, 60 8th St. NE., Atlanta, GA 30309, 404–347–7355.

Atlanta District Office, chaired by John H. Turner, District Director. The topics to be discussed are health messages on food labels and cholesterol labeling.

DATE: Wednesday, May 27, 1987, 11 a.m. to 1 p.m.

ADDRESS: North Fulton Government Annex, 7741 Roswell Rd. NE., Atlanta, GA 30338.

FOR FURTHER INFORMATION CONTACT: Carolyn Hommel, Consumer Affairs Officer, Food and Drug Administration, 60 8th St. NE., Atlanta, GA 30309. 404–347–7355.

SUPPLEMENTARY INFORMATION: The purpose of these meetings is to encourage dialogue between consumers and FDA officials, to identify and set priorities for current and future health concerns, to enhance relationships between local consumers and FDA's District Offices, and to contribute to the agency's policymaking decisions on vital issues.

Dated: May 14, 1987.

John M. Taylor,

Associate Commissioner for Regulatory Affairs.

[FR Doc. 87–11454 Filed 5–19–87; 8:45 am]

BILLING CODE 4160–01–M

Public Health Service

National Committee on Vital and Health Statistics; Meeting

Pursuant to the Federal Advisory Act (Pub. L. 92–463), notice is hereby given that the National Committee on Vital and Health Statistics (NCVHS) established pursuant to 42 U.S.C. 242k, section 306(k)(2) of the Public Health Service Act, as amended, will convene on Wednesday, June 3, 1987 from 1:30 p.m. to 5:00 p.m., Thursday, June 4, 1987 from 9:00 a.m. to 5:00 p.m. and Friday, June 5, 1987 from 9:00 a.m. to 1:00 p.m. in Room 703A of the Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201.

The Committee will receive reports from each of its Subcommittees and may address new business as appropriate.

Further information regarding this meeting of the Committee may be obtained by contacting Gail F. Fisher, Ph.D., Executive Secretary, National Committee on Vital and Health Statistics, Room 2–28, Center Building, 3700 East-West Highway, Hyattsville, Maryland 20782, telephone (301) 436–7050.

Dated: May 7, 1987.

Robert A. Israel,

Deputy Director, National Center for Health Statistics.

[FR Doc. 87–11483 Filed 5–19–87; 8:45 am]

BILLING CODE 4160–17–M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[CA–050–07–4351–12]

Availability of Draft Management Plan Amendment, Shasta River Salmon Spawning Area of Critical Environmental Concern (ACEC); and Environmental Assessment

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice of availability of draft plan amendment and environmental assessment.

DATE: Comments will be accepted until July 20, 1987.

SUMMARY: The intent of this amendment is to establish a portion of the Shasta River as an area of critical environmental concern (ACEC) for the protection of Chinook salmon, which spawn in this area. Management as an ACEC would require a Plan of Operations for gold dredging with dredges larger than three inches and a 50 foot "no disturbance" buffer strip above and below each weir constructed in the river to hold spawning gravel. Comments should be sent to: Robert J. Bainbridge, Redding Resource Area Manager, Bureau of Land Management, Redding Area Office, 355 Hemsted Drive, Redding, CA 96002, 916–246–5325.